SRR5088844
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.700
- INTERFERON_GAMMA_RESPONSE+0.600
- ALLOGRAFT_REJECTION+0.500
- IL6_JAK_STAT3_SIGNALING+0.300
- INFLAMMATORY_RESPONSE+0.300
- MYC_TARGETS_V2+0.300
- WNT_BETA_CATENIN_SIGNALING+0.300
- APICAL_SURFACE+0.200
- HEDGEHOG_SIGNALING+0.200
- MYC_TARGETS_V1+0.200
Top 10 suppressed
- ANGIOGENESIS-0.400
- E2F_TARGETS-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- G2M_CHECKPOINT-0.300
- UV_RESPONSE_DN-0.300
- COAGULATION-0.200
- ESTROGEN_RESPONSE_LATE-0.200
- GLYCOLYSIS-0.200
- MITOTIC_SPINDLE-0.200
- MYOGENESIS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 0ae6d322-a938-4752-aac6-226e6687a297 | — | — | 0.716 |
| 2 | DRR168511 | — | — | 0.703 |
| 3 | 6c0e101a-5eeb-46c7-9143-e78dc144d503 | — | — | 0.701 |
| 4 | SRR2660032 | — | — | 0.691 |
| 5 | TCGA-CV-A6JO-01B-11R-A34R-07 | — | — | 0.688 |
| 6 | s0112210 | — | — | 0.683 |
| 7 | SRR27320680 | — | — | 0.680 |
| 8 | 20080305.TNBC | — | D | 0.678 |
| 9 | MNG443 | — | — | 0.677 |
| 10 | 5ed0377f-26aa-4b4c-bb59-03001895aecd | — | — | 0.676 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.700 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |